AcuCort confirms reply dossier to the Swedish MPA regarding ISICORT® market application
AcuCort AB (Spotlight Stock Market: ACUC) has completed the reply dossier in response to the Primary Round Assessment Report from the Swedish Medical Products Agency (MPA), regarding the national Market Authorization Application (MAA) for ISICORT®. The reply dossier was submitted as planned on May 8th.As reported on February 13[th ]2020, AcuCort received the Primary Round Assessment Report including an overview and question list from the Swedish Medical Products Agency (MPA) in February. The Primary Round Assessment is the first formal step after Market Authorization Application (MAA),